We are live on
!
Find out more
ADMA Biologics
ADMA
ADMA
52 hedge funds and large institutions have $58M invested in ADMA Biologics in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
0% more call options, than puts
Call options by funds: $2K | Put options by funds: $2K
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
4.22% less ownership
Funds ownership: 57.5% → 53.28% (-4.2%)
10% less funds holding
Funds holding: 58 → 52 (-6)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
65% less capital invested
Capital invested by funds: $165M → $58M (-$107M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
52
Holders Change
-6
Holders Change %
-10.34%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
7
Increased
17
Reduced
18
Closed
12
Calls
$2K
Puts
$2K
Net Calls
–
Net Calls Change
-$5K
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$657K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$312K |
| 4 |
DG
Delek Group
Herzliya,
Israel
|
+$297K |
| 5 |
CCM
Consonance Capital Management
New York
|
+$243K |
Top Sellers
| 1 |
PVI
Pura Vida Investments
New York
|
-$2.65M |
| 2 |
BC
Broadfin Capital
New York
|
-$1.18M |
| 3 |
Renaissance Technologies
New York
|
-$1.17M |
| 4 |
JP Morgan Chase
New York
|
-$986K |
| 5 |
KC
Kepos Capital
New York
|
-$664K |
